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Reply
We thank Dr. Morice and colleagues for sharing their data
regarding reasons for implanting a bare metal stent (BMS) in
preference to a drug-eluting stent (DES). In their series, a BMS
was chosen because of the need for noncardiac surgery (NCS)
within the next year in 5.5% of patients, an incidence similar to
that reported in previous studies (1).We completely agree with the authors that a sizable percentage
of BMSs are implanted to avoid the risks associated with long-
term dual antiplatelet therapy (DAPT). We also agree with the
authors’ ideal DES, which would require only a limited period of
DAPT after implantation. It is important to emphasize, as we
noted in our paper (1), that the actual major adverse cardiac event
risk after NCS, a well-known prothrombotic stimulus, remains
uncertain, both during the highest risk period (0 to 6 weeks after
stent implantation) and thereafter. Further, the value of DAPT to
prevent ischemic events during NCS, in the traditional high-risk
period and beyond, also is uncertain, as is the relative increased
bleeding risk from DAPT continuation. As there is a large cohort
of stent patients undergoing NCS, determining the benefit–risk
ratio of maintaining DAPT during NCS in a scientifically rigorous
study is a laudable goal.
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